ISIN | LU2041625141 |
---|---|
Valor Number | 49498037 |
Bloomberg Global ID | |
Fund Name | JSS Sustainable Equity - Future Health P EUR acc |
Fund Provider |
J. Safra Sarasin Investmentfonds AG
Basel, Switzerland Phone: +41 58 317 44 44 Web: www.jsafrasarasin.com |
Fund Provider | J. Safra Sarasin Investmentfonds AG |
Representative in Switzerland |
J. Safra Sarasin Investmentfonds AG Basel Phone: +41 58 317 44 00 |
Distributor(s) |
Bank J. Safra Sarasin AG Basel Phone: +41 58 317 44 00 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD). |
Peculiarities |
Current Price * | 90.40 EUR | 16.04.2025 |
---|---|---|
Previous Price * | 91.16 EUR | 15.04.2025 |
52 Week High * | 108.58 EUR | 30.08.2024 |
52 Week Low * | 88.80 EUR | 10.04.2025 |
NAV * | 90.40 EUR | 16.04.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 119,245,083 | |
Unit/Share Assets *** | 6,003,313 | |
Trading Information SIX |
YTD Performance | -11.30% |
31.12.2024 - 16.04.2025
31.12.2024 16.04.2025 |
---|---|---|
YTD Performance (in CHF) | -12.54% |
31.12.2024 - 16.04.2025
31.12.2024 16.04.2025 |
1 month | -11.65% |
17.03.2025 - 16.04.2025
17.03.2025 16.04.2025 |
3 months | -13.87% |
16.01.2025 - 16.04.2025
16.01.2025 16.04.2025 |
6 months | -15.33% |
16.10.2024 - 16.04.2025
16.10.2024 16.04.2025 |
1 year | -9.57% |
16.04.2024 - 16.04.2025
16.04.2024 16.04.2025 |
2 years | -15.32% |
17.04.2023 - 16.04.2025
17.04.2023 16.04.2025 |
3 years | -23.40% |
19.04.2022 - 16.04.2025
19.04.2022 16.04.2025 |
5 years | -2.61% |
16.04.2020 - 16.04.2025
16.04.2020 16.04.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
UnitedHealth Group Inc | 7.15% | |
---|---|---|
Danaher Corp | 6.12% | |
Eli Lilly and Co | 6.11% | |
Gilead Sciences Inc | 4.95% | |
Sanofi SA | 4.93% | |
Johnson & Johnson | 4.84% | |
Boston Scientific Corp | 4.59% | |
Novo Nordisk AS Class B | 4.53% | |
AbbVie Inc | 4.34% | |
AstraZeneca PLC | 4.03% | |
Last data update | 28.02.2025 |
TER | 1.99% |
---|---|
TER date | 31.10.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 2.00% |
Ongoing Charges *** | 1.97% |
SRRI ***
|
|
SRRI date *** | 31.03.2025 |